Dyne Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Dyne Therapeutics, a clinical-stage muscle disease company (Nasdaq: DYN), announced participation in several upcoming investor conferences. Management will engage in virtual fireside chats at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 2:40 p.m. ET; Stifel 2023 CNS Days on March 29, 2023, at 11:30 a.m. ET; and Guggenheim Genomic Medicines and Rare Disease Days on April 4, 2023, at 10:10 a.m. ET. live webcasts of these presentations will be available on the company’s website, with replays accessible for 90 days. Dyne focuses on innovative therapeutics for genetically driven muscle diseases, leveraging its FORCE™ platform.

WALTHAM, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in virtual fireside chats at the following investor conferences:

• Oppenheimer 33^rd Annual Healthcare Conference on Monday, March 13, 2023 at 2:40 p.m. ET
• Stifel 2023 CNS Days on Wednesday, March 29, 2023 at 11:30 a.m. ET
• Guggenheim Genomic Medicines and Rare Disease Days on Tuesday, April 4, 2023 at 10:10 a.m. ET
  

A live webcast of each presentation will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on Twitter, LinkedIn and Facebook.

Contact:

Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com
857-341-1203

FAQ

What conferences is Dyne Therapeutics participating in March 2023?

Dyne Therapeutics will participate in Oppenheimer 33rd Annual Healthcare Conference on March 13, Stifel 2023 CNS Days on March 29, and Guggenheim Genomic Medicines and Rare Disease Days on April 4.

What is the schedule for Dyne Therapeutics' investor presentations?

On March 13 at 2:40 p.m. ET, March 29 at 11:30 a.m. ET, and April 4 at 10:10 a.m. ET.

Where can I watch Dyne Therapeutics' conference webcasts?

Live webcasts can be viewed on Dyne Therapeutics' Investors & Media section of their website.

How long will Dyne Therapeutics' conference replays be available?

Replays of the presentations will be accessible for 90 days.

What is Dyne Therapeutics' focus in the biotechnology sector?

Dyne Therapeutics focuses on developing therapeutics for genetically driven muscle diseases using its proprietary FORCE™ platform.